4 January 2018 - - US-based developer of glycopolymer-based therapeutics for pulmonary disease Synspira has received up to a USD 3m award from the Cystic Fibrosis Foundation to advance clinical development of its lead candidate, SNSP113, for use in pulmonary complications of cystic fibrosis (CF), the company said.
SNSP113 is a glycopolymer-based therapeutic being developed as an inhaled treatment to improve lung function in patients with cystic fibrosis.
As a modified polysaccharide molecule, SNSP113 interacts with structural polymers in protective bacterial biofilms, breaking them apart, and with native glycoproteins in mucus, reducing mucus viscosity and adhesion.
SNSP113 also interacts with the cell walls of invading bacteria increasing their permeability, thereby reducing their inherent viability and potentiating the efficacy of antibiotics.
Synspira is developing a new class of inhaled glycopolymer-based therapeutics to reduce pulmonary inflammation and infection, key drivers of pulmonary diseases including cystic fibrosis, chronic obstructive pulmonary disease, and pneumonia.
The company uses proprietary modified polysaccharide molecules to disrupt bacterial biofilms and to help expectorate mucus, exposing otherwise protected bacteria to antibiotics.
This new approach to the treatment of disease pathology has the potential to improve pulmonary function and reduce antibiotic resistance in a number of infectious diseases.